Comparison of short-term DAPT and long-term DAPT on the prognosis of PCI patients: a meta-analysis of randomized controlled trials [post]

Jiaxin Yang, Yaodong Ding, Rui Wang, Kexin Wang, Xiaoli Liu, Hua Shen, Yan Sun, Yujie Zhou, Hailong Ge, Zhe Fang
2022 unpublished
Background This article aimed to evaluate the safety and effectiveness of short-term (3–6 months) dual antiplatelet therapy (DAPT) compared to long-term (12 months) DAPT. Methods We searched PubMed, Embase, Cochrane Library, and Web of Science for all the randomized controlled trials which compared the different durations of DAPT after the percutaneous coronary intervention within ten years before January 2021. The safety endpoint included major bleeding and any bleeding. The efficacy endpoints
more » ... included all causes of death, cardiac death, myocardial infarction, definite or probable stent thrombosis, target vessel revascularization, and stroke. The hazard ratio and 95% confidence interval were abstracted. Result 11 trials and 24242 patients were finally included in this meta-analysis. Short-term DAPT was associated with a reduced risk of major bleeding [HR 0.65, 95%CI 0.48–0.89] and any bleeding [HR 0.64, 95%CI 0.53–0.79] compared with long-term DAPT. No significant differences in the risks of other endpoints were observed. In acute coronary syndrome, short-term DAPT was associated with a lower risk of major bleeding [HR 0.57, 95%CI 0.37–0.87]. Conclusion Compared with long-term DAPT, short-term DAPT reduced bleeding after PCI with DES. Besides, short-term DAPT was also feasible and safely applicable if clinically required even in ACS patients.
doi:10.21203/ fatcat:efdyl7ocvjffjbstf5hlbchdma